Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Benefits of Research Must Be Returned to the People: Mr Toguchi
September 24, 2007
- New Sales Strategy Going Extremely Well: Mr Kashiwagi of sanofi-aventis
September 24, 2007
- Breast Cancer Will Be One of the Major Topics in Women's Health Week: Mr Nishiyama
September 24, 2007
- AltaCare Provides Int. Sales, Business Dev. Services for Pharma, Consumer Care Products
September 24, 2007
- REGULATORY NEWS IN BRIEF
September 24, 2007
- Eli Lilly Enters GP Market with Cialis
September 24, 2007
- Boehringer Ingelheim to Initiate PIII Study for BIBW2992
September 24, 2007
- Taiyo Yakuhin's Outsourcing Study Group Focuses on Barrier Isolators
September 24, 2007
- 303 Orphan Drugs under Development in US
September 24, 2007
- Boehringer Ingelheim Ties Up with Ablynx for Nanobody Therapeutics
September 24, 2007
- Takara Bio Licenses Anticancer Immunotherapy to Korean Company
September 24, 2007
- Nihon Medi-Physics, Nippon Kayaku to Handle Metastron of GE Healthcare
September 24, 2007
- Environment Assuring Rapid Supply of New Anticancer Drugs Needed
September 24, 2007
- NBI Moves Its Tokyo Office to Osaki
September 24, 2007
- Development of New PPAR Agonists Extremely Difficult: Dr Obayashi
September 24, 2007
- Innovex, So-net M3 to Provide MR Activities Assessing Service
September 24, 2007
- Need to Legalize GL on Clinical Research Stressed by Committee Members
September 24, 2007
- Kyowa Hakko Recalls Coniel Tab due to Contamination Problem
September 24, 2007
- R&D NEWS IN BRIEF
September 24, 2007
- Diovan Remains No. 1 for 4 Consecutive Months
September 17, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…